Author:
Dannarm Srinivas Reddy,Harini Dharipally,Reddy Gangireddy Navitha,Ali Nazish,Sonti Rajesh
Subject
Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry
Reference34 articles.
1. Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials;Sax;eClinicalMedicine,2023
2. Co-formulated bictegravir, versus dolutegravir for initial treatment of HIV-1 infection: week 96 results from a phase 3, non-inferiority trial;Stellbrink;Lancet HIV,2019
3. Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection;Deeks;Drugs,2018
4. Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected Adults;Gallant;J. Acquir Immune Defic. Syndr.,2017
5. Bictegravir, a novel integrase inhibitor for the treatment of HIV infection;Zeuli;Drugs Today (Barc. ).,2019